Objective
Research objectives and content
E1A protein is involved in regulation of gene expression, apoptosis and cell differentiation. It interacts with p300/CBP, pRB and related pocket proteins. It is believed that E1A acts by sequestering its targets, therefore inhibiting their interaction with other proteins. Since p400 and p270 are potentially new members of the p300/CBP protein family, I aim to understand their role in cell cycle differentiation and transcriptional regulation. p400 and p270 will be isolated by immunopurification. It is known that p300/CBP is capable of acetylating histones and contribute in transcription regulation. In order to study this part of the gene activation, I will study the interaction between p400 and p270 with p300 associated histone acetylation factors, such as P/CAF. Most proteins that interact with P/CAF keep the cell cycle in check, presumably by turning on genes that inhibit cell growth while turning off those that might foster cell division. E1A binding to p300/CBP displaces P/CAF from the complex, and this may alter the acetylation activity, allowing expression of genes that enable cells to start dividing and preventing the expression of genes that inhibit cell division. The effects of p400 and p270 on cell cycle progression and transcriptional regulation will be analysed by using FACS analysis and E2F mediated enhancement.
Training content (objective, benefit and expected impact)
The research described, aims to further our understanding of the p300/CBP protein family. This study will be of fundamental importance in understanding the cell cycle progression and differentiation in both normal and malignant cells. In addition, this study can link the basic research with industrial applications, since it may lead to the design of molecules functioning as tumour suppressors and thus the production of new therapeutic agents. The results of this study may have therapeutic implications specifically in treatment of cancer. This research may be beneficial for the expansion of the knowledge and of innovative scientific methods in less favoured regions of the European Union (Greece). Links with industry / industrial relevance (22)
Professor N. La Thangue has a close connection with the European bio-pharmaceutical company Prolifix. As such, information derived from this research which is of relevance to proliferative diseases can be rapidly evaluated for its therapeutic value.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
G12 8QQ GLASGOW
United Kingdom
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.